Supervised lifestyle intervention from a medical professional may help maximize fat loss and minimize muscle tissue loss in people taking the potent weight loss drugs.

Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are ...

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

Presentation Title: Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass and Physical Function in Older Patients Receiving Semaglutide for Weight Loss Date: April 30, 2025 Start time: 12:30 ...

Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemesThe ...

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

Cade Shadbolt, from the University of Melbourne in Australia, and colleagues examined data from the Medical Expenditure Panel Survey Household Component from 2018 to 2022 to examine GLP-1 RA use ...